Researchers created a fusion protein combining interferon-alpha and thymosin alpha-1 that retained both antiviral and immune-stimulating activities. The fusion protein showed stronger anti-hepatitis B virus activity in laboratory tests than either drug used separately, with less cellular toxicity, suggesting it could be a more effective single-agent treatment option.
Liu, Xianjun; Liu, Fangxin; Li, Bo; Zhou, Huiyun; Wang, Qinqin